Prelude Therapeutics Incorporated (PRLD)
NASDAQ: PRLD · Real-Time Price · USD
4.390
-0.130 (-2.88%)
At close: Apr 28, 2026, 4:00 PM EDT
4.190
-0.200 (-4.56%)
After-hours: Apr 28, 2026, 5:40 PM EDT
Prelude Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 12.14 | 7 | - | - | - | |
| Revenue Growth (YoY) | 73.43% | - | - | - | - | |
| Gross Profit | 12.14 | 7 | - | - | - | |
| Selling, General & Admin | 22.31 | 28.72 | 28.88 | 30.65 | 26.96 | |
| Research & Development | 93.1 | 118 | 103.39 | 92.89 | 86.78 | |
| Operating Expenses | 115.41 | 146.71 | 132.28 | 123.54 | 113.74 | |
| Operating Income | -103.27 | -139.71 | -132.28 | -123.54 | -113.74 | |
| Other Non Operating Income (Expenses) | 5.07 | 12.54 | 10.45 | 8.1 | 2.04 | |
| EBT Excluding Unusual Items | -98.2 | -127.17 | -121.83 | -115.44 | -111.69 | |
| Merger & Restructuring Charges | -1.3 | - | - | - | - | |
| Pretax Income | -99.5 | -127.17 | -121.83 | -115.44 | -111.69 | |
| Net Income | -99.5 | -127.17 | -121.83 | -115.44 | -111.69 | |
| Net Income to Common | -99.5 | -127.17 | -121.83 | -115.44 | -111.69 | |
| Shares Outstanding (Basic) | 77 | 76 | 60 | 47 | 46 | |
| Shares Outstanding (Diluted) | 77 | 76 | 60 | 47 | 46 | |
| Shares Change (YoY) | 1.52% | 25.60% | 27.41% | 2.87% | 269.03% | |
| EPS (Basic) | -1.29 | -1.68 | -2.02 | -2.44 | -2.43 | |
| EPS (Diluted) | -1.29 | -1.68 | -2.02 | -2.44 | -2.43 | |
| Free Cash Flow | -56.37 | -103.65 | -110.58 | -86.75 | -85.85 | |
| Free Cash Flow Per Share | -0.73 | -1.37 | -1.83 | -1.83 | -1.86 | |
| Gross Margin | 100.00% | 100.00% | - | - | - | |
| Operating Margin | -850.63% | -1995.91% | - | - | - | |
| Profit Margin | -819.59% | -1816.76% | - | - | - | |
| Free Cash Flow Margin | -464.32% | -1480.74% | - | - | - | |
| EBITDA | -101.56 | -137.94 | -131.11 | -122.22 | -112.82 | |
| D&A For EBITDA | 1.71 | 1.77 | 1.17 | 1.32 | 0.92 | |
| EBIT | -103.27 | -139.71 | -132.28 | -123.54 | -113.74 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.